The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects

@inproceedings{Langenickel2016TheEO,
  title={The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects},
  author={Thomas H Langenickel and Chiaki Tsubouchi and Surya Ayalasomayajula and Parasar Pal and Marie‐Anne Valentin and Markus Hinder and Stanford S Jhee and Hakop Gevorkyan and Iris Rajman},
  booktitle={British journal of clinical pharmacology},
  year={2016}
}
AIMS LCZ696 (angiotensin receptor neprilysin inhibitor) is a novel drug developed for the treatment of heart failure with reduced ejection fraction. Neprilysin is one of multiple enzymes degrading amyloid-β (Aβ). Its inhibition may increase Aβ levels. The potential exists that treatment of LCZ696, through the inhibition of neprilysin by LBQ657 (an LCZ696 metabolite), may result in accumulation of Aβ. The aim of this study was to assess the blood-brain-barrier penetration of LBQ657 and the… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials.

Alzheimer's & dementia : the journal of the Alzheimer's Association • 2015

Similar Papers

Loading similar papers…